Obexelimab [1690307-05-1]

BPS Bioscience

Obexelimab [1690307-05-1]

23

Functional Assay, Flow Cytometry

1690307-05-1

Research Use Only

Monoclonal

≥95% by SEC-HPLC.

CD19

CD19 molecule

B4, CVID3, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12, differentiation antigen CD19

Hamster

IgG1

B-lymphocyte antigen CD19

Obexelimab, also known as XmAb5871, is a humanized IgG1 kappa anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc gamma receptor IIb (FcgammaRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

-80°C

41116161

Human